About this trial
The objective of this study is to extend our prior research by conducting a pragmatic implementation trial using a parallel-group, cluster randomized design to evaluate the PPP-CCM's ability to improve access to DAAs for HCV within a network of permanent supportive housing (PSH) buildings in Seattle and King County. The study will implement PPP-CCM to 16 housing buildings, randomizing half to receive PPP-CCM (intervention) versus usual care (UC) for 12-months, after which all buildings will have access to PPP-CCM. All buildings will have access to point-of-care HCV screening for the first 6 months of the study. Study outcome data will be collected through a longitudinal cohort-study of persons who screened positive for HCV which will conduct surveys and review of medical records at baseline, 12- and 24-months.
Eligibility criteria
Qualifiers
Adult ≥18 years of age
Currently a resident at one of DESC's PSH buildings at the time of study enrollment
Positive HCV test documented (screening antibody test or viral load test)
Provides release of information (ROI) to access community pharmacy electronic medical records (EHR) and/or other HCV treatment providers for information on HCV care during the study period between baseline visit and 24-month visit
Disqualifiers
Taking medications to treat HCV at the start of the study
Cognitive impairment (acute or chronic) resulting in inability to provide informed consent
Currently or impending incarceration
People who plan to leave the Seattle area within 24 months
Trial design
Treatments tested in this trial
- PPP-CCM
Treatment groups
Sponsors and collaborators
University of Washington
Lead sponsor
National Institute on Drug Abuse (NIDA)
Collaborator